(Q37731632)

22 August 2017

1 reference

title

Treat early, treat appropriately (English)

1 reference

22 August 2017

Andreas Liebl

1

1 reference

PubMed ID

20394889

22 August 2017

Guy Rutten

series ordinal

2

1 reference

PubMed ID

20394889

22 August 2017

Carlos Abraira

series ordinal

3

1 reference

22 August 2017

1 April 2010

1 reference

22 August 2017

Primary Care Diabetes

1 reference

22 August 2017

4 Suppl 1

1 reference

22 August 2017

S3-10

1 reference

Differences in treatment regimes, consultation frequency and referral patterns of diabetes mellitus in general practice in five European countries.

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

The IMPROVE study--a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Quality of diabetes care in the UK: comparison of published quality-of-care reports with results of the Quality and Outcomes Framework for Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Pay-for-performance programs in family practices in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Prevalence, care, and outcomes for patients with diet-controlled diabetes in general practice: cross sectional survey

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Improvements in quality of clinical care in English general practice 1998-2003: longitudinal observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Population-based measurement of quality of diabetes care using HbA1c values in the state of Thuringia/Germany

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Evaluation of a diabetes management system based on practice guidelines, integrated care, and continuous quality management in a Federal State of Germany: a population-based approach to health care research

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Insulin therapy in type 2 diabetes is no longer a secondary care activity in the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study.

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Insulin therapy in type 2 diabetes: what is the evidence?

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Glucose control and vascular complications in veterans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Card

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study

1 reference

https://api.crossref.org/works/10.1016%2FS1751-9918%2810%2960003-4

7 January 2021

10.1016/S1751-9918(10)60003-4

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20394889